LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SK-BR-3 | Mitoxantrone | 0.04 | uM | LJP6 | 3 | C24 | 72 | hr | 1476 | 1516 | 3694 | 0.4104 | 0.0177 |
SK-BR-3 | MK2206 | 0.04 | uM | LJP6 | 1 | F06 | 72 | hr | 1476 | 3469 | 3694 | 0.9391 | 0.8985 |
SK-BR-3 | MK2206 | 0.04 | uM | LJP6 | 2 | F06 | 72 | hr | 1476 | 3442 | 3694 | 0.9318 | 0.8863 |
SK-BR-3 | MK2206 | 0.04 | uM | LJP6 | 3 | F06 | 72 | hr | 1476 | 3206 | 3694 | 0.8679 | 0.7799 |
SK-BR-3 | Neratinib | 0.04 | uM | LJP5 | 1 | A18 | 72 | hr | 1476 | 1492 | 3694 | 0.4039 | 0.0069 |
SK-BR-3 | Neratinib | 0.04 | uM | LJP5 | 2 | A18 | 72 | hr | 1476 | 1262 | 3694 | 0.3416 | -0.0968 |
SK-BR-3 | Neratinib | 0.04 | uM | LJP5 | 3 | A18 | 72 | hr | 1476 | 1292 | 3694 | 0.3498 | -0.0833 |
SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 1 | N18 | 72 | hr | 1476 | 3754 | 3694 | 1.0162 | 1.0270 |
SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 2 | N18 | 72 | hr | 1476 | 3637 | 3694 | 0.9846 | 0.9743 |
SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 3 | N18 | 72 | hr | 1476 | 4045 | 3694 | 1.0950 | 1.1583 |
SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 1 | H06 | 72 | hr | 1476 | 3851 | 3694 | 1.0425 | 1.0708 |
SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 2 | H06 | 72 | hr | 1476 | 3910 | 3694 | 1.0585 | 1.0974 |
SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 3 | H06 | 72 | hr | 1476 | 3711 | 3694 | 1.0046 | 1.0076 |
SK-BR-3 | NU7441 | 0.04 | uM | LJP5 | 1 | C12 | 72 | hr | 1476 | 4009 | 3694 | 1.0853 | 1.1420 |
SK-BR-3 | NU7441 | 0.04 | uM | LJP5 | 2 | C12 | 72 | hr | 1476 | 4054 | 3694 | 1.0974 | 1.1623 |
SK-BR-3 | NU7441 | 0.04 | uM | LJP5 | 3 | C12 | 72 | hr | 1476 | 3832 | 3694 | 1.0373 | 1.0622 |
SK-BR-3 | Dactolisib | 0.04 | uM | LJP5 | 1 | M18 | 72 | hr | 1476 | 1669 | 3694 | 0.4518 | 0.0867 |
SK-BR-3 | Dactolisib | 0.04 | uM | LJP5 | 2 | M18 | 72 | hr | 1476 | 1723 | 3694 | 0.4664 | 0.1111 |
SK-BR-3 | Dactolisib | 0.04 | uM | LJP5 | 3 | M18 | 72 | hr | 1476 | 2014 | 3694 | 0.5452 | 0.2423 |
SK-BR-3 | NVP-TAE684 | 0.04 | uM | LJP6 | 1 | K18 | 72 | hr | 1476 | 3803 | 3694 | 1.0295 | 1.0491 |
SK-BR-3 | NVP-TAE684 | 0.04 | uM | LJP6 | 2 | K18 | 72 | hr | 1476 | 3996 | 3694 | 1.0817 | 1.1362 |
SK-BR-3 | NVP-TAE684 | 0.04 | uM | LJP6 | 3 | K18 | 72 | hr | 1476 | 3919 | 3694 | 1.0609 | 1.1015 |
SK-BR-3 | Palbociclib | 0.04 | uM | LJP6 | 1 | E18 | 72 | hr | 1476 | 3496 | 3694 | 0.9464 | 0.9107 |
SK-BR-3 | Palbociclib | 0.04 | uM | LJP6 | 2 | E18 | 72 | hr | 1476 | 3410 | 3694 | 0.9231 | 0.8719 |
SK-BR-3 | Palbociclib | 0.04 | uM | LJP6 | 3 | E18 | 72 | hr | 1476 | 3554 | 3694 | 0.9621 | 0.9368 |